Livnat Jerby
Overview
Explore the profile of Livnat Jerby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yeh C, Aguirre K, Laveroni O, Kim S, Wang A, Liang B, et al.
Nat Immunol
. 2024 Aug;
25(10):1943-1958.
PMID: 39179931
The drivers of immune evasion are not entirely clear, limiting the success of cancer immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to delineate immune evasion in high-grade serous...
2.
Tooley K, Jerby L, Escobar G, Krovi S, Mangani D, Dandekar G, et al.
Cell Rep Med
. 2024 Jul;
5(7):101640.
PMID: 38959885
CD8 T cells must persist and function in diverse tumor microenvironments to exert their effects. Thus, understanding common underlying expression programs could better inform the next generation of immunotherapies. We...
3.
Anderson A, Yanai I, Yates L, Wang L, Swarbrick A, Sorger P, et al.
Cancer Cell
. 2022 Sep;
40(9):895-900.
PMID: 36099884
Spatial transcriptomics, with other spatial technologies, has enabled scientists to dissect the organization and interaction of different cell types within the tumor microenvironment. We asked experts to discuss some aspects...
4.
Boroughs A, Larson R, Marjanovic N, Gosik K, Castano A, Porter C, et al.
Mol Ther
. 2020 Aug;
28(12):2577-2592.
PMID: 32755564
T cells engineered to express chimeric antigen receptors (CARs) targeting CD19 have produced impressive outcomes for the treatment of B cell malignancies, but different products vary in kinetics, persistence, and...
5.
Hyotylainen T, Jerby L, Petaja E, Mattila I, Jantti S, Auvinen P, et al.
Nat Commun
. 2016 Feb;
7:8994.
PMID: 26839171
Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leading to chronic liver disease and type 2 diabetes. Here we chart liver metabolic activity and functionality in NAFLD by...
6.
Zheng L, Cardaci S, Jerby L, MacKenzie E, Sciacovelli M, Johnson T, et al.
Nat Commun
. 2015 Jan;
6:6001.
PMID: 25613188
Mutations in the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) are associated with a highly malignant form of renal cancer. We combined analytical chemistry and metabolic computational modelling to...
7.
Jerby L, Ruppin E
Clin Cancer Res
. 2012 Oct;
18(20):5572-84.
PMID: 23071359
The metabolism of cancer cells is reprogrammed in various ways to support their growth and survival. Studying these phenomena to develop noninvasive diagnostic tools and selective treatments is a promising...
8.
Jerby L, Wolf L, Denkert C, Stein G, Hilvo M, Oresic M, et al.
Cancer Res
. 2012 Sep;
72(22):5712-20.
PMID: 22986741
Aberrant metabolism is a hallmark of cancer, but whole metabolomic flux measurements remain scarce. To bridge this gap, we developed a novel metabolic phenotypic analysis (MPA) method that infers metabolic...
9.
Frezza C, Zheng L, Folger O, Rajagopalan K, MacKenzie E, Jerby L, et al.
Nature
. 2011 Aug;
477(7363):225-8.
PMID: 21849978
Fumarate hydratase (FH) is an enzyme of the tricarboxylic acid cycle (TCA cycle) that catalyses the hydration of fumarate into malate. Germline mutations of FH are responsible for hereditary leiomyomatosis...
10.
Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T
Mol Syst Biol
. 2011 Jun;
7:501.
PMID: 21694718
The interest in studying metabolic alterations in cancer and their potential role as novel targets for therapy has been rejuvenated in recent years. Here, we report the development of the...